Researchers at the University of Kentucky are exploring a potential new use for an experimental dementia drug. Known as MW150, this medication might help ease alcohol withdrawal by reducing brain inflammation linked to addiction and relapse.

MW150 targets a specific brain inflammation pathway called p38α MAPK. Although the drug is yet to be approved, it was initially developed to treat mild to moderate Alzheimer’s disease.

Research Findings

Studies at the University of Kentucky’s Sanders-Brown Center on Aging demonstrated that MW150 could lower inflammatory markers during alcohol withdrawal. This research was led by neuroinflammation researcher Linda Van Eldik and published in the journal Alcohol.

Caleb Bailey, Ph.D., a co-author of the study, stated that their findings offer “biological plausibility” that MW150 may mitigate neuroinflammation caused by alcohol withdrawal. The persistent relapse and withdrawal in alcohol use disorder present significant treatment challenges.

Potential for Broader Application

Alongside MW150, a related drug called Neflamapimod, is under clinical trial as a treatment for dementia and other neurodegenerative diseases. According to Bailey, this progress suggests that these drugs could be re-purposed for alcohol-related conditions in the future.

However, the researchers caution that the study’s findings are based on cell culture and animal models. Bailey emphasized the need for more studies on living organisms to better understand the impact of MW150 on alcohol use and withdrawal.

Expert Opinions

Dr. Amy Swift, deputy chief medical officer at Silver Hill Hospital, noted the importance of supportive medications in early alcohol detoxification. Although not involved in the study, she acknowledged the potential of reducing neuroinflammation to aid recovery from alcohol use disorder.

Swift stated, “Detoxification using tapering doses of medication is an evidence-based first step, but it doesn’t treat the disorder itself. Adding supportive medications could play a crucial role.”

Bailey pointed out that “no amount of alcohol consumption is beneficial to health.” He emphasized minimizing alcohol use as crucial for overall health and highlighted the need for robust pharmacological treatments to counteract alcohol’s damage.

As studies on the MW150 compound continue, understanding its interaction with alcohol will be vital for improving patient outcomes.